	Correction to "Active surveillance for patients with prostate cancer aged â‰¥75â€‰years: the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study". BJU Int PMID: 42643147 [PubMed - as supplied by publisher]
	Boosting Diagnostic Accuracy of Prostate Cancer: Combining Clinical PSA Level and a Pair of NIR Fluorescent Probes for SLC39A1 and PSMA. Angew Chem Int Ed Engl Huo X, Yang F, Wang H, Chen J, She M, Xue L, Liu P, Zhang S, Li J. PMID: 42643071 [PubMed - as supplied by publisher]
	Patient-Reported Outcome Instruments in Non-Muscle-Invasive Bladder Cancer (NMIBC): A Systematic Review. Oncol Ther Griebsch I, Shrestha S, Gotay CC, Gore JL, Curtis F, Bottomley A. PMID: 42642612 [PubMed - as supplied by publisher]
	Explainable artificial intelligence reveals key surgical parameters in robot-assisted and open radical prostatectomy. Sci Rep Klein CR, Heuser P, Trunz E, Kristiansen G, Brossart P, Ritter M, Krausewitz P. PMID: 42642558 [PubMed - indexed for MEDLINE]
	Initial Experience With a Step-Specific Reconstructive Strategy During Robot-Assisted Radical Cystectomy Using the da Vinci SP System. Asian J Endosc Surg Kamiyama Y, Abe S, Hoshiyama A, Nishikawa Y, Tsutsumi N, Kajita Y, Segawa T. PMID: 42642183 [PubMed - indexed for MEDLINE]
	Histone Erasers in Prostate Cancer: Clearing the Path for Progression & Therapy Resistance. Crit Rev Oncol Hematol Cevatemre B, Bulut P, Yuksel-Catal N, Karyemez E, Yildiz D, Acilan C. PMID: 42641833 [PubMed - as supplied by publisher]
	Immune checkpoint inhibitor combinations across clinically distinct metastatic renal cell carcinoma populations with limited or heterogeneous trial evidence: a systematic review, evidence map, and meta-analysis. Crit Rev Oncol Hematol Wang Y, Qu H, Zhou X, Li J, Zhang Z. PMID: 42641831 [PubMed - as supplied by publisher]
	Embarking on a new era in high-risk biochemical recurrent prostate cancer: redefining early systemic intervention. Pharmacol Ther Izzi M, Lapucci A, Catalano M, Vascotto IA, Calandrelli C, Mancini S, Pratesi L, Mela MM, Rossi V, Pillozzi S, Koatale PC, Roberts R, Matthews D, Cerbone L, Perrella A, Santoni M, Antonuzzo L, Roviello G. PMID: 42641694 [PubMed - as supplied by publisher]
	Diagnosis of Clinically Significant Prostate Cancer in Multiparametric MRI with Pseudo-Localization of Suspected Lesion. Phys Med Biol Liu X, Liu R, Zhou X, Yan Y, He H, Zhou Q, Zhang L, Zhang Q. PMID: 42641644 [PubMed - as supplied by publisher]
	GPNMB expression in clear cell papillary renal cell tumour: Limited specificity and a potential diagnostic pitfall in clear cell renal neoplasms. Ann Diagn Pathol Skopal J, Alaghehbandan R, Slisarenko M, Vanecek T, Hajkova V, Ptáková N, Rogala J, Ulamec M, Kuthi L, Pavlovsky M, Dolezilek R, Berouskova P, Takacova M, Horava V, Bobot L, Pidima P, Sikova D, Khomenko K, Pitra T, Hora M, Fiala O, Michal M, Ondic O, Pivovarcikova K. PMID: 42641476 [PubMed - as supplied by publisher]
	Ultrasound Radiomics for Differential Diagnosis of Renal Masses: A Systematic Review and Meta-Analysis. Technol Cancer Res Treat Xu Y, Zhang S, Wang Y, Lin H, Liu W, Lu X, Zhang X, Liu Y, Li N. PMID: 42640784 [PubMed - indexed for MEDLINE]
	LRRC8A as a candidate biomarker of cisplatin sensitivity in muscle-invasive bladder cancer: an exploratory immunohistochemical study. Int Urol Nephrol Rytz MA, Hussung S, Frehner L, Beyer J, Scheidewind L, Roth B, Widmer C, Baaral A, Francica P, Rubin MA, Rottenberg S, Rodriguez-Calero A, Akhoundova D. PMID: 42640415 [PubMed - as supplied by publisher]
	Neuroendocrine Neoplasms of the Urinary Bladder: Integrating Molecular Advances into a Refined Classification System. Endocr Pathol Lobo A, Cheng L. PMID: 42640400 [PubMed - indexed for MEDLINE]
	Clinical value of prostate-specific antigen halving time as a predictor of response to first-line systemic treatment for synchronous metastatic castration-sensitive prostate cancer. Int J Clin Oncol Kambe T, Sumiyoshi T, Fujiwara H, Fujimoto T, Takahashi T, Mizuno K, Kubota M, Yamasaki T, Yoshimura K, Tamaki M, Nagumo Y, Kawanishi H, Miyazaki Y, Oshiro H, Kurahashi R, Masuda N, Makino Y, Kobori G, Akamatsu S, Morita S, Kobayashi T, Goto T. PMID: 42640376 [PubMed - as supplied by publisher]
	Dynamic Predictions and Predictimands for Salvage Therapy in Recurrent Prostate Cancer Using Joint Models. Stat Med Owens L, Rizopoulos D, Fainberg J, Carlsson S, Liso N, McBride S, Laudone V, Etzioni R, Taylor JMG. PMID: 42639747 [PubMed - indexed for MEDLINE]
	Stage-Specific Temporal Trends in Treatment Patterns and Overall Survival in Prostate Cancer: A Multicentre Real-World Cohort Study From KAMU-ON. Int J Urol Iwamoto H, Izumi K, Machioka K, Toriumi R, Shima T, Nozaki M, Hori T, Inaba T, Nakagawa R, Kamijima T, Kadomoto S, Makino T, Naito R, Yaegashi H, Shigehara K, Nohara T, Miyagi T, Seto C, Kadono Y, Mizokami A. PMID: 42639687 [PubMed - indexed for MEDLINE]
	Hereditary Prostate Cancer Risk Management: An Evidence-Based Summary to Inform Nursing Practice. J Multidiscip Healthc Jiang M, Chen Q, Chen X, Fu X, Chung SK. PMID: 42639254 [PubMed]
	Regulatory T cells in the bladder cancer tumor microenvironment: mechanisms of immune suppression and therapeutic opportunities. Front Mol Biosci Fukiage Y, Okubo N, Taga M, Sato Y, Terada N. PMID: 42639050 [PubMed]
	Urinary protein semi-quantification in immunochemotherapy for bladder cancer: markers of clinical outcomes. Front Immunol Chen H, Lin Y, Xue Z, Qie Y, Wu Z, Liu K, Huang S, Jia K, Yang S, Zhang Z, Li P, Li X, Liu L, Shen C, Hu H. PMID: 42639047 [PubMed - indexed for MEDLINE]
	Beyond supplements and surrogates: an evidence-quality map informs a strategic rebalancing of dietary research in prostate cancer active surveillance. Front Nutr Li Y, Wang TQ, Zhu AY, Zhang YP, Fu Q. PMID: 42638961 [PubMed]

Articles 1 - 20 / 180974

Page 1 of 9049



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy